Citigroup Inc Theseus Pharmaceuticals, Inc. Call Options Transaction History
Citigroup Inc
- $169 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding THRX
# of Institutions
2Shares Held
1.03MCall Options Held
0Put Options Held
0About Theseus Pharmaceuticals, Inc.
- Ticker THRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,713,400
- Description
- Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...